by admin | 28th July 2023 | News
London and New York, NY – July 28, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this... by admin | 28th July 2023 | News
New York, July 28, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant...
by admin | 28th July 2023 | News
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP Second clinical indication for OK-101 which is currently in 240 patient phase 2 clinical... by admin | 27th July 2023 | News
LONDON and NEW YORK, July 27, 2023– OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is... by admin | 6th June 2023 | News
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain component Top-line data from trial anticipated in Q4, 2023 London and New York, NY, June 6, 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an...
